📊 ETON Key Takeaways
Is Eton Pharmaceuticals, Inc. (ETON) a Good Investment?
Eton demonstrates exceptional revenue growth (105% YoY) with impressive free cash flow generation (30.2% FCF margin), indicating strong product market fit and operational execution. However, weak returns on capital (ROE 5.1%), suboptimal liquidity (0.88x quick ratio), and narrow interest coverage (2.1x) present execution and balance sheet risks that require monitoring.
Eton Pharmaceuticals is showing strong fundamental momentum, with revenue more than doubling year over year and free cash flow turning meaningfully positive, which suggests its growth is translating into real cash generation. The main constraint is that profitability is still not fully established, with negative net income, thin operating margin, and weak interest coverage, but the business appears close to operating breakeven with a manageable liquidity position.
Eton Pharmaceuticals, Inc. Key Strengths (ETON)
- Exceptional revenue growth of 104.9% YoY demonstrating strong product adoption and market traction
- Outstanding free cash flow generation with $7.3M FCF and 30.2% FCF margin showing efficient cash conversion
- Healthy gross margins of 60.7% indicating pricing power or manufacturing efficiency
- Positive net income profitability with profitable operations despite small-cap scale
- Moderate leverage (0.62x D/E ratio) with adequate equity base for a pharma growth company
- Revenue growth of 104.9% YoY indicates strong commercial execution and expanding product contribution
- Positive operating cash flow of $10.52M and free cash flow of $10.19M show improving earnings quality and cash conversion
- Gross margin of 53.5% and cash balance of $25.94M provide a reasonable foundation for continued scaling
ETON Stock Risks: Eton Pharmaceuticals, Inc. Investment Risks
- Poor returns on capital with ROE of 5.1% and ROA of 1.6% suggesting inefficient asset deployment
- Weak liquidity position with 0.88x quick ratio below 1.0 creating vulnerability to short-term obligations
- Limited interest coverage at 2.1x indicating debt service pressure if revenues decline
- Operating margin compression at 9.9% despite 60.7% gross margins points to cost control challenges
- Small-cap scale with $30.6M equity limiting financial flexibility and ability to weather sector downturns
- Pharma sector risks including product approval uncertainty, patent expiration, and competitive pressures
- Net income remains negative at -$4.60M, showing the company has not yet achieved durable bottom-line profitability
- Interest coverage of -0.2x indicates current operating earnings do not adequately cover financing costs
- Debt/equity of 0.83x and relatively modest equity base increase balance sheet sensitivity if growth slows
Key Metrics to Watch
- Operating leverage improvement and operating margin expansion to demonstrate cost control
- Quick ratio trend and working capital management for liquidity stability
- Debt reduction trajectory and interest coverage ratio sustainability
- Revenue growth sustainability and gross margin maintenance
- Cash conversion cycle and operating cash flow consistency with revenue growth
- Operating margin progression toward sustained positive EBIT
- Free cash flow durability alongside revenue growth
Eton Pharmaceuticals, Inc. (ETON) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 30.2% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
ETON Profit Margin, ROE & Profitability Analysis
ETON vs Healthcare Sector: How Eton Pharmaceuticals, Inc. Compares
How Eton Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Eton Pharmaceuticals, Inc. Stock Overvalued? ETON Valuation Analysis 2026
Based on fundamental analysis, Eton Pharmaceuticals, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Eton Pharmaceuticals, Inc. Balance Sheet: ETON Debt, Cash & Liquidity
ETON Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Eton Pharmaceuticals, Inc.'s revenue has grown significantly by 266% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.04 indicates the company is currently unprofitable.
ETON Revenue Growth, EPS Growth & YoY Performance
ETON Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $17.3M | $1.6M | $0.05 |
| Q3 2025 | $10.3M | $627.0K | $0.02 |
| Q2 2025 | $9.1M | -$2.6M | N/A |
| Q1 2025 | $8.0M | -$811.0K | N/A |
| Q3 2024 | $7.0M | -$579.0K | $-0.02 |
| Q2 2024 | $9.1M | $1.9M | $0.07 |
| Q1 2024 | $5.3M | -$811.0K | $-0.03 |
| Q3 2023 | $3.2M | -$579.0K | $-0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Eton Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
ETON SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Eton Pharmaceuticals, Inc. (CIK: 0001710340)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ETON
What is the AI rating for ETON?
Eton Pharmaceuticals, Inc. (ETON) has a Combined AI Grade of A from Claude (A) and ChatGPT (A) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ETON's key strengths?
Claude: Exceptional revenue growth of 104.9% YoY demonstrating strong product adoption and market traction. Outstanding free cash flow generation with $7.3M FCF and 30.2% FCF margin showing efficient cash conversion. ChatGPT: Revenue growth of 104.9% YoY indicates strong commercial execution and expanding product contribution. Positive operating cash flow of $10.52M and free cash flow of $10.19M show improving earnings quality and cash conversion.
What are the risks of investing in ETON?
Claude: Poor returns on capital with ROE of 5.1% and ROA of 1.6% suggesting inefficient asset deployment. Weak liquidity position with 0.88x quick ratio below 1.0 creating vulnerability to short-term obligations. ChatGPT: Net income remains negative at -$4.60M, showing the company has not yet achieved durable bottom-line profitability. Interest coverage of -0.2x indicates current operating earnings do not adequately cover financing costs.
What is ETON's revenue and growth?
Eton Pharmaceuticals, Inc. reported revenue of $24.3M.
Does ETON pay dividends?
Eton Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find ETON SEC filings?
Official SEC filings for Eton Pharmaceuticals, Inc. (CIK: 0001710340) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ETON's EPS?
Eton Pharmaceuticals, Inc. has a diluted EPS of $0.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ETON's fundamental grade?
Based on our AI fundamental analysis in June 2026, Eton Pharmaceuticals, Inc. has a A grade with 70% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is ETON stock overvalued or undervalued?
Valuation metrics for ETON: ROE of 5.1% (sector avg: 15%), net margin of 6.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ETON's AI grade for 2026?
Our dual AI analysis gives Eton Pharmaceuticals, Inc. a combined A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ETON's free cash flow?
Eton Pharmaceuticals, Inc.'s operating cash flow is $7.4M, with capital expenditures of $75.0K. FCF margin is 30.2%.
How does ETON compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 6.4% (avg: 12%), ROE 5.1% (avg: 15%), current ratio 1.21 (avg: 2).